Eli Lilly and Company (NYSE:LLY) announced on November 9, 2026, positive Phase 3 results from the ATTAIN-OSA clinical program evaluating Foundayo (orforglipron) in adults with moderate-to-severe obstructive sleep apnea and obesity or overweight, with results presented at the American Heart Association Scientific Sessions 2026 and simultaneously published in JAMA.

Key Highlights

  • Primary endpoint met: Foundayo reduced AHI events by 21.1 per hour (43.8%) at 52 weeks in participants not using PAP therapy, from an average baseline of 50.7 events per hour.
  • Remission or mild disease: 31.5% of participants not using PAP therapy achieved remission or mild OSA after 52 weeks of Foundayo treatment.
  • Hypoxic burden reduction: Foundayo reduced sleep apnea-specific hypoxic burden by 81.4 percent-minutes per hour (55.9%) in participants not using PAP therapy.
  • Weight loss observed: Participants taking Foundayo lost an average of 28.0 lbs (11.5%) without PAP therapy and 28.2 lbs (11.2%) with PAP therapy.
  • Cardiovascular risk factors improved: Foundayo lowered hsCRP by an average of 48.9% and systolic blood pressure by an average of 8.6 mmHg in participants not using PAP therapy.
  • FDA submission planned: Lilly disclosed plans to submit Foundayo to the U.S. FDA for moderate-to-severe OSA in adults with obesity or overweight by the end of 2026.
  • Safety profile: Discontinuation rates due to adverse events with Foundayo vs. placebo were 12.2% vs. 3.8% among participants not using PAP therapy.

ATTAIN-OSA Phase 3 Results: Foundayo's Effect on Sleep Apnea Severity and Cardiovascular Risk Factors

According to the announcement, the ATTAIN-OSA program comprised two studies evaluating Foundayo in adults with moderate-to-severe OSA and obesity or overweight, one in participants not using positive airway pressure (PAP) therapy and one in those using PAP therapy. In Study 1 (no PAP therapy), Foundayo reduced AHI events by 21.1 per hour compared with a reduction of 4.3 per hour for placebo, from an average baseline of 50.7 events per hour. In Study 2 (PAP therapy users), Foundayo reduced AHI events by 18.3 per hour versus 5.5 per hour for placebo, from an average baseline of 57.6 events per hour. The filing noted that 47.2% of Study 1 participants achieved an AHI reduction of 50% or more, and 33.7% of Study 2 participants did the same.

The company disclosed that Foundayo also improved secondary endpoints. Sleep apnea-specific hypoxic burden fell by 75.0 percent-minutes per hour (45.8%) in PAP therapy users. Body weight declined from average baselines of 110.2 kg (242.9 lbs) and 114.6 kg (252.6 lbs) in the two studies, respectively. The filing reported reductions in hsCRP of 48.9% and 38.6%, and systolic blood pressure reductions of 8.6 mmHg and 7.3 mmHg, in participants not using and using PAP therapy, respectively.

Regarding safety, the filing stated that the most common adverse events were gastrointestinal, including nausea, diarrhea, constipation, dyspepsia, and vomiting, and were "generally mild to moderate in severity." The overall safety and tolerability profile was described as "generally consistent with previous trials in the ACHIEVE and ATTAIN programs." Foundayo is disclosed as a once-daily oral small molecule GLP-1 receptor agonist already approved in the U.S. for adults with obesity.

What Was Disclosed

Lilly disclosed Phase 3 ATTAIN-OSA trial results showing Foundayo significantly reduced AHI, hypoxic burden, body weight, blood pressure, and inflammation in adults with moderate-to-severe OSA and obesity or overweight, and announced plans to submit Foundayo to the FDA for this indication by the end of 2026.